InvestSMART

AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD
Current share price for 1AD : $0.004 0.001 (33.33%)+
Announcement
Release
10 Aug 2026 9:18AM
Price at Release
$0.003
Full Release
download
Summary
AdAlta Limited has provided an update on the Investigator Initiated Trial (IIT) of its lead CAR-T cell therapy, EW-001, for treating mesothelioma. The report highlights the continued survival of all five patients on study as of July 2026, with emerging trends of longer survival at higher EW-001 doses. Over half of the patients treated at higher doses have shown a positive overall response, with two achieving complete responses. AdAlta plans to test even higher doses in an upcoming Australian Phase 1 study. The company is also transferring manufacturing processes to Cell Therapies Pty Ltd in Australia and preparing for a pre-IND meeting with the US FDA. These steps are part of AdAlta's strategy to integrate Asian T cell therapy advancements with Australia's clinical and manufacturing efficiencies, aiming to provide novel treatments for solid cancers.
Key Points
  • AdAlta's EW-001 IIT shows continued patient survival in mesothelioma study.
  • Higher doses of EW-001 correlate with better patient outcomes.
  • AdAlta preparing for Australian Phase 1 study and US regulatory engagement.
  • EW-001 shows promising response rates compared to existing treatments.
  • AdAlta integrates Asian innovations with Australian clinical capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.